Advertisement
Survey Series
Institutions
For Advertisers
|
|
||||
|
Therapeutic MAbs: Saving Lives and Making Billions
Monoclonal antibodies spur a lucrative new period in biomedicine
Email: Kelli Miller Stacy - kstacy@the-scientist.com The Scientist 2005, 19(3):17
|
||||
|
|
||||
|
In 1895 two French physicians attempted a radical departure from the standard cancer treatment regimen. Instead of surgery, Charles Richet and Jules Hericourt administered an antiserum derived from dogs to patients with advanced cancer.[1]
Some patients improved, although significant immunogenicity problems occurred. Lacking specificity and purity, the formulation cured no one.
|
|
|||||||||
|
|||||||||
|
